Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Ichiro Otsuka Becomes Chairman of Otsuka Holdings
March 30, 2015
- Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
- Genzyme Japan Receives Approval for Japan’s 1st Oral Gaucher’s Disease Treatment Cerdelga
March 30, 2015
- E Keppra Filed for Generalized Tonic-Clonic Seizures: Otsuka, UCB Japan
March 30, 2015
- Takeda Seeks Japan Approval for Single-Packs Containing Takecab for H. pylori Eradication
March 27, 2015
- Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
- Xtandi Significantly Extends OS, Lowers Risk of Death by 23%
March 26, 2015
- Santen Ups FY2014 Financial Outlook on Merck Asset Acquisition
March 26, 2015
- Sun Pharma Completes Merger with Ranbaxy; Daiichi Sankyo Owns 9% Share in Combined Firm
March 26, 2015
- Yoshiki Ito to Lead Merged Entity of Allergan, Actavis in Japan
March 25, 2015
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
- Investigational Duchenne Muscular Dystrophy Drug Shows Favorable Results: Nippon Shinyaku, NCNP
March 25, 2015
- AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
- Opdivo Wins South Korean Approval: Ono
March 24, 2015
- Takeda to Set Up Japan Oncology, Vaccine Business Units as Part of Corporate Reorganization
March 24, 2015
- Merck KGaA Gauging Regional Priorities for PD-L1 Inhibitor Development: Exec
March 24, 2015
- Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
- Pfizer Japan Voluntarily Recalls Generic Gemcitabine
March 23, 2015
- Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono
March 20, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…